Farmak’s Chief Information Officer became the winner in Leader of Efficiency nomination of Investgazeta’s Top CIOs of Ukraine Rating.
The awards ceremony of Ukraine’s Top CIO Rating was held on 14 November 2013. The rating determined 40 top CIOs of Ukrainian companies, four of which became winners in special nominations, including Leader of Efficiency, Leader of Change, Leader of Innovations, and IT Strategist.
The list of experts, who evaluated each of over 120 nominees on the long list, included the representatives of consulting companies, well-known vendors, and key CIO stakeholders: vendors and developers, managing directors, IT consultants, winners of the Top CFO and HR manager ratings, and representatives of Top Ten CEOs (as part of TOP 100 rating).
The nominees were rated by several criteria: information technology management function, vision and strategy, accomplishments, financial performance, feedback, internal IT processes, team and innovations.
Georgiy Kondrashykhin became the winner in special Leader of Efficiency nomination, where financial performance, information technology management function, and accomplishments were evaluated.
Georgiy Kondrashykhin, Chief Information Officer, Farmak JSC, says, “Efficiency at Farmak means the coordinated work of the team, which serves all IT-processes. Our top-priority task is to ensure that every team member understands the goal and the ways of its achievement. The key success factor lies in the coordinated teamwork of IT-service and our colleagues from security department, accounting and management automation department, and engineering and technical department.”
Farmak, as a member of the European Generic Medicines Association (EGA) – Medicines for Europe – and the Association of “Manufacturers of Drugs of Ukraine” (the AMDU), advocates for the creation of a coordination group at the Office of the President of Ukraine to prevent a shortage of medicines in Ukraine during the pandemic. […]
The pharmaceutical company JSC “Farmak” considers the possibility of launching the manufacture of products, in particular, diagnostic test kits, to combat coronavirus spread. “Now we analyse the possibility of arranging the release of supportive care products, disinfectants and antiseptics, diagnostic test kits, protective medical products, including masks, ...
Farmak reinvests 95% of its profits in the development. “We have never paid more than 5% of our profits as dividends. We have reinvested everything in the development. Due to this, Farmak’s capitalization can be estimated at $850 million to $1 billion today. If I sell the shares that I hold, I will earn a […]